MGPI: Distilled Down to Value - Post-Earnings Review
Brought to you by Drew Millegan & The Woodworth Contrarian Fund
Woodworth Contrarian / Gemini 2026
MGP Ingredients (MGPI): Short Post-Earnings Value Review
MGP Ingredients looks more interesting after earnings than the headline loss suggests. The quarter was messy, but bottom-line adjusted profits of $0.15/share were overshadowed by non-cash accounting adjustments and write-downs ($6.45/share). Companies tend to take losses opportunistically when they believe it will do the least damage to their share value. Given MGPI’s depressed status, and the liquor industry itself is stuck in a perpetual hangover, the share price certainly seems oversold. In light of Q1 2026 earnings, the key question we should be asking ourselves is this: is it reasonable for the market to price MGPI as a permanently impaired business when management is still guiding $90 million to $98 million of adjusted EBITDA, $30 million to $35 million of free cash flow, and an improving leverage ratio for 2026?
Post-Earnings Read
Q1 itself was weak but not thesis-breaking. Sales fell 13 percent to $106.4 million, adjusted EBITDA declined 31 percent to $15.0 million, and adjusted EPS fell to $0.15, yet management said results were in line on sales and ahead of plan on EBITDA and EPS, while also reaffirming full-year guidance.
The GAAP loss looked far worse because MGPI recorded a $179.5 million non-cash impairment charge tied to goodwill and other long-lived assets in Branded Spirits, including $115.7 million of goodwill, $37.0 million of indefinite-lived intangibles, and about $26.9 million tied to Lux Row equipment. Management attributed the write-down primarily to higher discount rates and lower peer valuation multiples rather than a sudden collapse in near-term operating guidance.
Valuation
At roughly $20 per share in late April 2026, MGPI’s equity value was about $432 million to $434 million, while public market data placed enterprise value near $684 million. Against management’s reaffirmed 2026 adjusted EBITDA outlook of $90 million to $98 million, the shares trade at about 7.0x to 7.6x EV/EBITDA.
That multiple does not look demanding for a business that still owns branded spirits assets, an ingredients franchise, and distilling infrastructure, particularly if 2026 proves to be the trough year management described for Distilling Solutions. Using management’s 2026 free-cash-flow outlook of $30 million to $35 million excluding the Penelope earn-out, the stock is also trading at roughly a 6.9 percent to 8.1 percent free-cash-flow yield on current market cap.
Tangible book value, meanwhile, continues to escalate with every passing quarter, now clocking in at $17.52, or just shy of 1-to-1 with current share price. One year ago, tangible book value was just $14.71, an over 19% increase in tangible book value year-over-year.
Balance Sheet
The balance sheet is the main reason the value case remains investable rather than merely theoretical. As of March 31, 2026, MGPI had $10.4 million of cash ($0.48 per share), about $245.0 million of total debt ($11.86 per share), $234.6 million of net debt, and a net debt leverage ratio of approximately 2.1x. That is not light leverage, but it is manageable if EBITDA holds in the guided range and cash conversion improves through the year.
The more important point from the call was that management now expects 2026 operating cash flow of $50 million to $55 million and free cash flow of $30 million to $35 million ($1.40 to $1.64 per share), excluding the Penelope earn-out, and expects leverage to peak at about 3.5x, better than the 3.75x previously discussed. The temporary idling of Kentucky distilling was framed as a balance-sheet and working-capital decision driven by inventory alignment, not by a collapse in customer demand or a need for emergency liquidity.
Goodwill Write-Off
The impairment matters, but mostly as a reset. It confirms that prior spirits acquisition values were too aggressive for the current rate environment and peer valuation backdrop, but it does not by itself reduce cash flow or create solvency pressure. In that sense, the write-off may be less a reason to avoid the stock than an acknowledgment that the over-earning, over-valued phase is already behind it.
For a value investor, this distinction is critical. If the impairment were signaling a business that can no longer earn acceptable returns, the low multiple would be a trap; if it is instead an accounting reset during an industry downturn, today’s valuation may be discounting too bleak a future.
Price Target
A reasonable 12-month value target is $28 per share, with a longer-run target of $35 per share. That shorter run target assumes MGPI can deliver around the midpoint of 2026 EBITDA guidance, or roughly $94 million, and deserves an enterprise value multiple of about 8.0x on trough-to-recovery earnings, which implies enterprise value of about $752 million. After subtracting roughly $235 million of net debt, the implied equity value is about $517 million, which translates to approximately $24 per share on 21.4 million shares.
A short-run $28 target reflects the possibility that trough-year EBITDA understates normalized earnings power if Distilling Solutions stabilizes and Ingredient Solutions recovers margin into 2027, as management suggested. That upside framework is still conservative relative to many branded spirits valuations, but it appropriately respects the current uncertainty around whiskey inventories, portfolio execution, and ingredients margins.
Disclosure: This analysis is for informational purposes. MGPI remains a cyclical business with near-term headwinds and execution risk. Position sizing and risk management are essential. Do your own due diligence.
Please note that the Woodworth Contrarian Stock & Bond Fund, LP, of which the Millegan Brothers manage and are invested in, currently hold a position of MGPI as of the publication date of this article. They may or may not choose to modify their exposure to this name for any reason at any time. This is not a recommendation to buy or sell MGPI or any other name - investments incur significant risk, our risk tolerance may be significantly higher than the average investor, and any discussion in this article does not take into consideration your individual circumstances.
Additional reading:
DEEP ROOTS. STUBBORN GROWTH. OREGON-BASED.
Now is a great time to diversify your portfolio with an investment into an award-winning fund. Call us or visit our website to inquire on an investment today in the Woodworth Contrarian Fund as an accredited investor.
(800) 651-1996 - info@woodworth.fund - www.Woodworth.Fund
Contrarian Value-Based Hedge Fund of the Year 2022-2024
Quinn Millegan (left) & Drew Millegan (right)
About the Managers: Brothers Drew Millegan and Quinn Millegan manage the Woodworth Contrarian Stock & Bond Fund, a hedge fund based in McMinnville, Oregon. They grew up in the finance world, and specialize in contrarian investment strategies in the US Public and Private markets.
Something missing from your portfolio may be a diversification into the Woodworth Contrarian Fund for accredited investors. Now is a great time to diversify your portfolio with an investment into a multi-award-winning fund. An exposure to a value-based contrarian strategy is a unique opportunity for your long term capital that you’re seeking aggressive returns for. With nine years of the Woodworth Fund under management, the Millegan Brothers are trained stock-pickers and experienced venture capital investors with a proven track record. Give us a call today to discuss a liquid investment with independent administration and independently audited monthly statements and a personal relationship.
